Protein Kinase Inhibitors: all 15,278 studies that test it

Page 41 of 153. Open to participants first (2,558), then studies with results posted, then the rest; newest registration first within each.

• Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity ImpairmentCompletedNCT02788474Phase 4Results posted
• A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)CompletedNCT02788279Phase 3Results posted
• Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .CompletedNCT02788006Phase 2Results posted
• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung CancerCompletedNCT02785939Phase 2/3Results posted
• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker MatchesCompletedNCT02785913Phase 2Results posted
• Long-Term Side Effects of Ruxolitinib in Treating Patients With MyelofibrosisCompletedNCT02784496Phase 2Results posted
• Safety and Efficacy Study of M2951 in Participants With Rheumatoid ArthritisCompletedNCT02784106Phase 2Results posted
• A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's DiseaseCompletedNCT02782663Phase 2Results posted
• Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)CompletedNCT02781584Phase 2Results posted
• Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]TerminatedNCT02780700Phase 2Results posted
• Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based ChemotherapyCompletedNCT02780687Phase 2Results posted
• Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic DermatitisCompletedNCT02780167Phase 2Results posted
• Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast CancerActive, not recruitingNCT02778685Phase 2Results posted
• Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's SyndromeCompletedNCT02775916Phase 2Results posted
• Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain MetastasisTerminatedNCT02774681Phase 2Results posted
• A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02774278Phase 2Results posted
• Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung CancerTerminatedNCT02770014Phase 2Results posted
• Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)CompletedNCT02766465Phase 2Results posted
• Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)Active, not recruitingNCT02764541Phase 2Results posted
• A Study of Abemaciclib (LY2835219) in Participants With Breast CancerActive, not recruitingNCT02763566Phase 3Results posted
• Expansion Trial for Axitinib In Head And Neck CancerCompletedNCT02762513Phase 2Results posted
• Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations (MK-4440-001)TerminatedNCT02761694Phase 1Results posted
• Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results posted
• A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02760485Phase 1/2Results posted
• Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With OsimertinibCompletedNCT02759835Phase 2Results posted
• Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02759731Phase 1/2Results posted
• A Study of Baricitinib (LY3009104) in Healthy Chinese ParticipantsCompletedNCT02758613Phase 1Results posted
• ABC294640 (Opaganib) in Refractory / Relapsed Multiple MyelomaTerminatedNCT02757326Phase 1/2Results posted
• Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid NeoplasmsCompletedNCT02756572Phase 2Results posted
• Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor TherapyCompletedNCT02756364Phase 2Results posted
• A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard ChemotherapyCompletedNCT02752035Phase 3Results posted
• Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung CancerTerminatedNCT02751385Phase 1Results posted
• An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT02750514Phase 2Results posted
• A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET InhibitorCompletedNCT02750215Phase 2Results posted
• C. Difficile and UrsodiolCompletedNCT02748616Phase 4Results posted
• A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast CancerCompletedNCT02747004Phase 2Results posted
• Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02744612Phase 2Results posted
• Evaluate the Efficacy and Safety of TGR-1202 in Participants With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior TherapyTerminatedNCT02742090Phase 2Results posted
• Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820TerminatedNCT02739360Phase 4Results posted
• ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) ParticipantsCompletedNCT02737501Phase 3Results posted
• Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell LymphomaCompletedNCT02736617Phase 2Results posted
• A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung CancerCompletedNCT02735980Phase 2Results posted
• Study of Pexidartinib in Asian Subjects With Advanced Solid TumorsCompletedNCT02734433Phase 1Results posted
• Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMDCompletedNCT02732899Phase 2Results posted
• Investigating the Interactions of AZD0530 With Alcohol in Social DrinkersCompletedNCT02732587Phase 1Results posted
• Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.CompletedNCT02732119Phase 1/2Results posted
• Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell CarcinomaCompletedNCT02729194Early Phase 1Results posted
• Copanlisib in Treating Patients With Persistent or Recurrent Endometrial CancerCompletedNCT02728258Phase 2Results posted
• Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeCompletedNCT02728050Phase 1/2Results posted
• Phase II Study of TAK228 in Relapsed LymphomaTerminatedNCT02727777Phase 1/2Results posted
• A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial CancerCompletedNCT02725268Phase 2Results posted
• MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaCompletedNCT02724020Phase 2Results posted
• Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid TumorsCompletedNCT02723864Phase 1Results posted
• Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy VolunteersCompletedNCT02723630Phase 1Results posted
• Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedNCT02723006Phase 1Results posted
• Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic SyndromesTerminatedNCT02721875Phase 1Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDsCompletedNCT02720523Phase 2/3Results posted
• Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFRTerminatedNCT02720185Phase 2Results posted
• Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)CompletedNCT02720068Phase 1Results posted
• Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast CancerCompletedNCT02719691Phase 1Results posted
• A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisTerminatedNCT02718300Phase 2Results posted
• A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyActive, not recruitingNCT02717611Phase 2Results posted
• Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT02713386Phase 1/2Results posted
• Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast CancerActive, not recruitingNCT02712723Phase 2Results posted
• A Long-term, Continued Treatment and Follow-up Study in Participants With Hematologic Malignancies Treated With Duvelisib (IPI-145)CompletedNCT02711852Phase 2Results posted
• Treg Therapy in Subclinical Inflammation in Kidney TransplantationCompletedNCT02711826Phase 1/2Results posted
• A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerActive, not recruitingNCT02711553Phase 2Results posted
• A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.TerminatedNCT02711345Phase 1Results posted
• Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney TransplantationCompletedNCT02711202Not applicableResults posted
• Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid LeukemiaTerminatedNCT02709083Phase 2Results posted
• A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)CompletedNCT02708095Phase 2Results posted
• A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)CompletedNCT02706951Phase 3Results posted
• A Study to Compare Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have Not Previously Taken MethotrexateCompletedNCT02706873Phase 3Results posted
• A Study to Compare Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) With an Inadequate Response or Intolerance to Biologic DMARDsCompletedNCT02706847Phase 3Results posted
• BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck CancerTerminatedNCT02706691Phase 2Results posted
• Trial of Brigatinib After Treatment With Next-Generation ALK InhibitorsTerminatedNCT02706626Phase 2Results posted
• A Study of PRN1008 in Adult Patients With Pemphigus VulgarisCompletedNCT02704429Phase 2Results posted
• A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin LymphomaTerminatedNCT02703272Phase 3Results posted
• A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety ProfileCompletedNCT02702388Phase 2Results posted
• Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)TerminatedNCT02701634Phase 2Results posted
• Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary DiseaseCompletedNCT02700919Phase 2Results posted
• A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic TumorsCompletedNCT02699749Phase 1Results posted
• Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)TerminatedNCT02695290Phase 4Results posted
• A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic CancerCompletedNCT02694536Phase 3Results posted
• Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast CancerCompletedNCT02692755Phase 2/3Results posted
• Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCTCompletedNCT02692248Phase 2Results posted
• To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy VolunteersCompletedNCT02690727Phase 1Results posted
• A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary FibrosisCompletedNCT02688647Phase 2Results posted
• A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the BodyCompletedNCT02688088Phase 1Results posted
• Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid TumorsCompletedNCT02686164Phase 1Results posted
• Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155/KEYNOTE-155)TerminatedNCT02684617Phase 1Results posted
• Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG TumorsCompletedNCT02684058Phase 2Results posted
• A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)CompletedNCT02684006Phase 3Results posted
• Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast CancerCompletedNCT02679755Phase 4Results posted
• Lenvatinib Efficacy in Metastatic Neuroendocrine TumorsCompletedNCT02678780Phase 2Results posted
• A Study of Abemaciclib in Healthy ParticipantsCompletedNCT02677844Phase 1Results posted
• A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs AloneCompletedNCT02675426Phase 3Results posted
• A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast CancerCompletedNCT02675231Phase 2Results posted
• Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC AlterationsCompletedNCT02674750Phase 2Results posted
• Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast CancerCompletedNCT02673398Phase 2Results posted

← Protein Kinase Inhibitors overview